Skip to main content
Clinical Trials/NCT02265900
NCT02265900
Terminated
Not Applicable

Exercise and Parkinson's Disease: The Basis for Motor and Cognitive Benefits

Pacific Parkinson's Research Centre1 site in 1 country26 target enrollmentNovember 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Parkinson Disease
Sponsor
Pacific Parkinson's Research Centre
Enrollment
26
Locations
1
Primary Endpoint
Change in Dopamine release measured by RAC PET
Status
Terminated
Last Updated
5 years ago

Overview

Brief Summary

The therapeutic effects of exercise in Parkinson's disease (PD) are commonly reported, however the mechanisms are unknown. The purpose of this study is to investigate the potential mechanisms of exercise in the brain for the treatment of PD.

Detailed Description

Positron Emission Tomography will be used to measure dopamine neuron density, endogenous dopamine release and neuroimflammation. We will also use functional magnetic resonance imaging (fMRI) to measure brain activity. Assessments will be conducted before and after a 12-week exercise intervention and 3-year follow-up. Participants will be randomly allocated into either an aerobic or a stretching intervention. Clinical measures of motor function, cognition and mood will also be assessed.

Registry
clinicaltrials.gov
Start Date
November 2014
End Date
March 12, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Pacific Parkinson's Research Centre
Responsible Party
Principal Investigator
Principal Investigator

A. Jon Stoessl

Director of Clinical PET

Pacific Parkinson's Research Centre

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with Parkinson's Disease, Exercise less than 3x per week.
  • Exclusion Criteria. Describe which potential participants will be excluded from participation, and list the criteria for their exclusion.
  • atypical Parkinson syndrome (progressive supranuclear palsy, multiple system atrophy, drug-induced etc.);
  • significant osteoporosis or arthritis;
  • other neurological disease/complications (e.g. myopathy, stroke, brain lesion, MS);
  • self-reports claustrophobia;
  • history of cancer within 5 years of study participation;
  • high dose of radiation from other procedures within the year;
  • not able to tolerate being off PD medication for up to 24 hours;
  • a female subject who is breast-feeding or pregnant.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Change in Dopamine release measured by RAC PET

Time Frame: 4 months

Study Sites (1)

Loading locations...

Similar Trials